NASDAQ:AQST | Free Cash Flow | Aquestive Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$14.81M$52,000.00-$14.86M
2025-12-31-$8.47M$85,000.00-$8.55M
2025-03-31-$23.4M$135,000.00-$23.54M
2024-12-31-$6.49M$15,000.00-$6.5M
2024-03-31-$10.38M$29,000.00-$10.41M
2023-12-31-$4.94M$16,000.00-$4.96M
2023-03-31$8.82M$2,000.00$8.81M109.25%
2022-12-31$8.42M$26,000.00$8.39M
2022-03-31-$14.48M$104,000.00-$14.59M
2021-12-31-$8.06M$533,000.00-$8.59M
2021-03-31-$14.1M$103,000.00-$14.2M
2020-12-31-$13.51M$236,000.00-$13.75M
2020-03-31-$13.64M$131,000.00-$13.77M
2019-12-31-$10.58M$86,000.00-$10.66M
2019-03-31-$17.68M$376,000.00-$18.06M
2018-12-31-$2.81M$490,000.00-$3.3M
2018-03-31$785,000.00$259,000.00$526,000.0012.83%
2017-12-31-$7.41M$88,000.00-$7.5M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$52.43M$562,000.00-$52.99M
2024-12-31-$35.76M$159,000.00-$35.92M
2023-12-31-$6.38M$995,000.00-$7.38M
2022-12-31-$9.82M$1.02M-$10.84M
2021-12-31-$32.98M$913,000.00-$33.89M
2020-12-31-$45.46M$517,000.00-$45.98M
2019-12-31-$60.21M$663,000.00-$60.87M
2018-12-31-$12.99M$1.82M-$14.82M
2017-12-31$5.82M$2.07M$3.76M